China National Biotech Group to Invest Over $263 Million in Diagnostic Reagent Production Base in Jilin

Shanghai. August 13. INTERFAX-CHINA - China National Biotech Group, China’s largest biological product manufacturer, will invest RMB 2 billion ($263.85 million) to set up a diagnostic reagent production base in the city of Jinlin in northwestern China’s Jilin Province, according to the Jinlin city government today.

MORE ON THIS TOPIC